论文部分内容阅读
日本13个临床单位对Tosufloxacin(T-3262)和头孢克罗治疗牙科、口腔外科感染的有效性、安全性和有用性进行了双盲比较。研究对象为牙周炎、牙冠周围炎、颌炎。T-3262每天给药量为450mg(分3次),头孢克罗为750mg(分3次),疗程3-7天。对246例进行了有效性评价,对255例进行了安全性评价。根据委员会判定,T-3262组的临床有效率为86.9%(106/122),头孢克罗组为85.5%(106/124)。按疾病种类分,对牙周炎,T-3262组的有效率为83.0%(39/47),头孢克罗组为80.0%(36/45);对牙冠周围炎,T-3262组为90.9%(30/33);头孢克罗组为84.6%
Thirteen clinical units in Japan conducted a double-blind comparison of the efficacy, safety and usefulness of Tosufloxacin (T-3262) and cefaclor in the treatment of dental and oral surgical infections. The object of study was periodontitis, peri-crownitis, jaw inflammation. T-3262 daily dose of 450mg (3 times), cefaclor 750mg (3 times), treatment of 3-7 days. 246 cases were evaluated for effectiveness and 255 cases for safety assessment. The committee determined that the clinical response rate was 86.9% (106/122) for the T-3262 group and 85.5% (106/124) for the cefaclor group. According to the type of disease, the effective rate of periodontitis was 83.0% (39/47) in T-3262 group and 80.0% (36/45) in cefaclor group. For T-3262 group 90.9% (30/33); cefaclor group was 84.6%